Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

fda Press Releases

  + XML/RSS  



By American Conference Institute
American Conference Institute (ACI) is proud to announce that its industry leading FDA Boot Camp conference is returning to Boston, MA on September 18-19, 2014.

By Alliance for Natural Health USA
Deceptive Labeling Confuses Consumers and Contradicts State Department Policies

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization

By Alliance for Natural Health USA
FDA guidelines are unconstitutional, violate the First Amendment and the Equal Protection Clause, and contravene Congressional intent.

By RxforAmericanHealth
A stance by the Pharmaceutical Research and Manufacturers of America (PhRMA) for the U.S.

By Cambridge Healthtech Institute
Bringing Industry, Academia and Regulatory Authorities Together to Produce Safe and Efficacious Products for the Clinic and Beyond

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By TodaysSeniorsNetwork
HHS Secretary urged to act to block needless destruction of safe, authentic personally imported prescription medicines

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts Record 1st Half 2014 Results Blockbuster HIV/AIDS Vaccine REMUNE Set to Become First HIV/AIDS Vaccine to File for FDA BLA Approval & Come to Market.

By cGMP UNIVERSITY INC
This seminar is designed for professionals in in the Medical Device, Pharmaceutical, and Biotech startup companies

By Q1 Productions
New One-Day Companion Diagnostics Course Added to Meeting Agenda

By American Conference Institute
American Conference Institute (ACI) is honored to have all three major associations for the Dietary Supplements Industry –namely the Natural Products Association (NPA), Counsel for Responsible Nutrition (CRN), and American Herbal Products Association...

By Mayday Project
On Thursday, May 22, 2014, Lyme disease victims from around the U.S. will unite at the Infectious Diseases Society of America (IDSA) headquarters for the 2014 Mayday Project protest.

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Breakthrough Designation of REMUNE HIV/AIDS Vaccine for Pediatric Treatment & Plans Phase II Pediatric Study.

By FDAnews
Traditional Approaches for Collaborating with Outsourced Manufacturers and Suppliers Are Failing FDAnews Free Webinar Sponsored by Veeva Systems May 13, 2014 — 1:00 p.m. – 2:00 p.m. EDT www.fdanews.com/SupplyChainCollaborationPR1

By Public Interest Law Professor John Banzhaf
The FDA reported that e-cigarettes pose “acute health risks” which “cannot seriously be questioned” because they contain “toxic chemicals,” and that the devices also “present a serious risk of addicting new users, including children.”

By Olympia Pharmacy
Olympia Compounding Pharmacy announced today it has voluntarily registered with the FDA as an outsourcing facility.

By SEMDA
Southeastern Medical Device Association (SEMDA) Addressing Reform Impact Head-on

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces the FDA SBA BLA Fee Waiver has been Granted & Clears a Path for the REMUNE HIV/AIDS Vaccine Approval

By Medicast Inc. And Expect Advertising, Inc.
“Continued use of non-approved drugs when a safe, FDA-approved product is available is not in the public interest and can lead to legal lawsuits.” — Cindy Ippoliti, Pharm.D., NYP/Weill Cornell

All Press Releases

By Public Interest Law Professor John Banzhaf
The WHO has just recommended very tough restrictions on e-cigarettes, including a total ban on their use in public places, regulations to ensure the products contain a standard dose of nicotine, and a ban on sales to children and the use of flavors

By American Conference Institute
American Conference Institute (ACI) is proud to announce that its industry leading FDA Boot Camp conference is returning to Boston, MA on September 18-19, 2014.

By Alliance for Natural Health USA
Deceptive Labeling Confuses Consumers and Contradicts State Department Policies

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Develop in house Sales-Force for Blockbuster REMUNE HIV/AIDS Vaccine Commercialization

By Alliance for Natural Health USA
FDA guidelines are unconstitutional, violate the First Amendment and the Equal Protection Clause, and contravene Congressional intent.

By RxforAmericanHealth
A stance by the Pharmaceutical Research and Manufacturers of America (PhRMA) for the U.S.

By Cambridge Healthtech Institute
Bringing Industry, Academia and Regulatory Authorities Together to Produce Safe and Efficacious Products for the Clinic and Beyond

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Approval for Expanded Use of Blockbuster HIV/AIDS Vaccine REMUNE for HIV/AIDS Monotherapy as it produces huge green shoots of CD8+ T cells Killer White Blood Cells

By TodaysSeniorsNetwork
HHS Secretary urged to act to block needless destruction of safe, authentic personally imported prescription medicines

By Q1 Productions
Social Media Implications, Solidifying Data for On-Site Presentation Among Key Topics

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Posts Record 1st Half 2014 Results Blockbuster HIV/AIDS Vaccine REMUNE Set to Become First HIV/AIDS Vaccine to File for FDA BLA Approval & Come to Market.

By cGMP UNIVERSITY INC
This seminar is designed for professionals in in the Medical Device, Pharmaceutical, and Biotech startup companies

By Q1 Productions
New One-Day Companion Diagnostics Course Added to Meeting Agenda

By Lisa OKeefe
Do you ever think your government isn't interested in what you have to say?

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Selects Seppic to Supply Incomplete Freund’s Adjuvants (IFA) for REMUNE HIV/AIDS Vaccine Commercialization & Pipeline

By American Conference Institute
American Conference Institute (ACI) is honored to have all three major associations for the Dietary Supplements Industry –namely the Natural Products Association (NPA), Counsel for Responsible Nutrition (CRN), and American Herbal Products Association...

By Mayday Project
On Thursday, May 22, 2014, Lyme disease victims from around the U.S. will unite at the Infectious Diseases Society of America (IDSA) headquarters for the 2014 Mayday Project protest.

By Public Interest Law Professor John Banzhaf
E-cigarettes may be a public health hazard by permitting users to continue smoking despite workplace smoking bans, encouraging kids to become addicted to nicotine, causing increased indoor air pollution, and encouraging smoking

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. to Seek FDA Breakthrough Designation of REMUNE HIV/AIDS Vaccine for Pediatric Treatment & Plans Phase II Pediatric Study.

By Public Interest Law Professor John Banzhaf
In the U.S., the FDA is proposing rules which would do little to rein in a product the agency itself has said pose “acute health risks” which “cannot seriously be questioned” because they contain “toxic chemicals.”

By FDAnews
Traditional Approaches for Collaborating with Outsourced Manufacturers and Suppliers Are Failing FDAnews Free Webinar Sponsored by Veeva Systems May 13, 2014 — 1:00 p.m. – 2:00 p.m. EDT www.fdanews.com/SupplyChainCollaborationPR1

By Public Interest Law Professor John Banzhaf
The FDA reported that e-cigarettes pose “acute health risks” which “cannot seriously be questioned” because they contain “toxic chemicals,” and that the devices also “present a serious risk of addicting new users, including children.”

By Professor John Banzhaf, GWU Law School
WASHINGTON, D.C. (April 14, 2014): Leaked documents indicate that electronic cigarettes, also known as e-cigarettes, may be zapped by the World Health Organization [WHO]

By Olympia Pharmacy
Olympia Compounding Pharmacy announced today it has voluntarily registered with the FDA as an outsourcing facility.

By SEMDA
Southeastern Medical Device Association (SEMDA) Addressing Reform Impact Head-on

By Immune Response BioPharma, Inc.
Immune Response BioPharma, Inc. Announces the FDA SBA BLA Fee Waiver has been Granted & Clears a Path for the REMUNE HIV/AIDS Vaccine Approval

By Aging in Motion
Experts from the FDA and Science, Industry and Advocacy Groups Discuss Strategies to Advance Treatment for Condition

By GlobalSubmit
Software Release Includes New Module 1 Specifications, Performance Enhancements

By Medicast Inc. And Expect Advertising, Inc.
“Continued use of non-approved drugs when a safe, FDA-approved product is available is not in the public interest and can lead to legal lawsuits.” — Cindy Ippoliti, Pharm.D., NYP/Weill Cornell

By Public Interest Law Professor John Banzhaf
A federal appeals court has ruled that law suits against food companies for misrepresentation are not preempted by federal law, opening the door even further to a growing wave of such suits,

By Public Interest Law Professor John Banzhaf
Many states - just now Missouri - are in danger of having their scheduled executions delayed or even stopped by law suits over the drugs to be injected, but there appears to be a simple remedy which avoids virtually all of the problems

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

By Farm Plus Financial Farm Loans
According to Farm Plus Financial Farm Loans at http://www.farmloans.com, the Food and Drug Administration recently took the first steps in banning the non-treatment-based use of antibiotics in US livestock, arguing that antibiotic abuse can lead to the...

By FDAnews
Device Supplier Controls: Does the FDA’s Next 483 Have Your Name on It? **FDAnews Virtual Conference** Feb. 26, 2014 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/SupplierControlsVCPR1

By Alliance for Natural Health USA
Sammy Hagar, Sen. Kelly Ayotte & 100,000 concerned citizens plead for agency to grant ‘Compassionate Use Exemption’

By Immune Response BioPharma Inc.
Immune Response BioPharma, Inc. Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.

By The Cornucopia Institute
On December 11, 2013 the U.S. Food & Drug Administration (FDA) released a guidance document that asks animal-drug makers to voluntarily discontinue marketing antibiotics to farmers for faster livestock growth, limiting their use strictly to therapeutic...

By Mary Ann Liebert, Inc., publishers
The U.S. Food and Drug Administration (FDA) mandates adequate enrollment of women in post-approval studies (PAS) of medical devices to ensure that any sex differences in device safety and effectiveness are not overlooked.

By Immunotech Laboratories Inc.
Immunotech laboratories (immb) is pleased to announce that the financials for auditing have been completed and are now in the process of being audited.

By Professor John Banzhaf, GWU Law School
Nicotine, the substance to which bystanders are exposed when e-cigarettes are used, are a key contributing factor in the almost 50,000 annual nonsmoker deaths from secondhand tobacco smoke - and bystanders deserve to be protected

By Immune Response BioPharma
Immune Response BioPharma Sets U.S. REMUNE Pricing Range $75-250 Per Dose with a Target of $100 or Less, Goal of $50 per dose, Once Commercial Manufacturing & Stockpiling is Secured on a Large Scale or a New Manufacturing Plant is Built.

By Immune Response BioPharma
Immune Response BioPharma, Inc., Announces its Plans to Develop Annual Preventative HIV/AIDS Vaccine RemuneVax IR-2020 Based on Current Mutated HIV Strain for Preventative Use.

By Public Interest Law Professor John Banzhaf
Simple Regulations Cost Nothing, and Are Much More Efficient

By Better Shea Butter
Better Shea Butter has recently launched a new zinc oxide powder that offers customers excellent value for money.

By FDAnews
Leverage New Tools for Device CAPA Compliance **FDAnews Virtual Conference** Dec. 19, 2013 — 10:00 a.m. – 4:00 p.m.

By Immune Response BioPharma
Immune Response BioPharma to File Remune BLA with FDA by March 1st 2014 & Submits Fee Waiver Request, IRBP also plans to Transition the Vaccine to Preventative Use.

By Immune Response BioPharma, Inc.
Immune Response BioPharma to Keep U.S. NeuroVax Rights for MS Expects Phase IIb Enrollment to Begin by Q2 2015.

By FDAnews
Ensuring Market Success Via Environmental Compliance: How RoHS and REACH Could Hamper Your EU Sales **FDAnews FREE Webinar** Nov. 20, 2013 — 1:30 p.m. – 3:00 p.m. EST www.fdanews.com/MarketSuccessPR1

By A.D. Allen
Research scientist publishes a review of a public health crisis in online journal ADVANCES IN AGING RESEARCH.

By FDAnews
The FDA Unique Device Identification (UDI) Rule It’s Ready for You, Are You Ready for It? **FDAnews Virtual Conference** Nov. 19, 2013 — 10:00 a.m. – 4:00 p.m. EST www.fdanews.com/UDIVirtualPR1



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share